Does Boston boast more brainiacs than anywhere else in the country?
By one measure it does.
The Howard Hughes Medical Institute, a nonprofit research organization, on Wednesday named 19 new medical investigators who will receive a total of $200 million to do whatever biomedical research they want. For the second time since 2013, roughly a third of the investigators were based in the Boston area, a greater concentration than any region in the country.
The institute, which was started in 1953 by the business magnate, aviator, and maverick film tycoon whose name it bears, will provide each investigator with $8 million over seven years. The term can be renewed after a scientific review. Recipients were picked from 675 eligible applicants.
“We selected these scientists because they know how to ask hard and interesting questions with skill and intellectual courage,” said David Clapham, vice president and chief scientific officer of the institute, which is based in Chevy Chase, Md. “We believe they have the potential to make breakthroughs over time.”
The six local investigators include microbiologist Thomas Bernhardt and cell biologist Stephen Liberles, both of Harvard Medical School; neuroscientist Edward Boyden of the Massachusetts Institute of Technology; Dr. Benjamin Ebert, an oncologist at Dana-Farber Cancer Institute; neuroscientist Beth Stevens of Boston Children’s Hospital; and Feng Zhang, a biochemist at MIT who helped pioneer the CRISPR gene editing technology.
Their research interests range from how to combat antibiotic resistance (Bernhardt) to cancer-causing mutations in blood cells that also predispose people to heart disease (Ebert), according to the institute.
“Every scientist is unique, but they all need one thing: time,” said institute president Erin O’Shea. “HHMI is dedicated to providing outstanding biomedical scientists with the time and resources to do their best work.”
Twenty-eight current or former HHMI scientists have won a Nobel Prize. Investigators have made leaps forward in HIV vaccine development, microbiome and circadian rhythm research, immunotherapy, and the genome editing tool known as CRISPR/Cas9, among other fields.
The institute names a new cadre of investigators roughly every three years. In 2013, nine of the 27 recipients were from Massachusetts, also more than from any other part of the country.
Because the funding has no strings attached, HHMI investigators are free to pursue their wildest scientific ideas. They don’t have to write grants and wait months to hear if they’ve won approval.
The money can be used partly to pay laboratory staff who help investigators, as well as other expenses.
Longtime HHMI investigators in the Boston area include Michael Rosbash, chair of neuroscience at Brandeis University and a Nobel laureate (an investigator since 1989), and Christine Seidman, director of the cardiovascular genetics center at Brigham and Women’s Hospital (an investigator since 1994), according to the institute.
Dr. George Q. Daley was an investigator from 2008 to 2017, when he resigned to become dean of Harvard Medical School.
‘We believe they have the potential to make breakthroughs over time.’— David Clapham, Howard Hughes Medical Institute
“It was one of my greatest sacrifices to resign from such an exciting community of scientists and to forfeit the unrestricted funding that allowed me to take major scientific risks,” Daley, a specialist in stem cell research, said. “Becoming an HHMI investigator counts among the highest privileges that any scientist can achieve.”Jonathan Saltzman can be reached at email@example.com.